Neurocritical Care

, Volume 19, Issue 1, pp 10–18 | Cite as

Analysis of the Delay Components in the Treatment of Status Epilepticus

Original Article

Abstract

Background

The factors comprising the delays in management of status epilepticus (SE) have not been systematically studied.

Methods

We studied retrospectively all adult patients (N = 82) diagnosed with SE in Helsinki University Central Hospital emergency room over a 2-year period. We analyzed prehospital, diagnostic, treatment, and treatment response delays based on medical records and quantitatively evaluated data availability and accuracy.

Results

SE manifested mostly without any warning symptoms, but every fifth case presented a pre-status period. Median prehospital delay was 2 h 4 min, including delays in emergency call, ambulance arrival, and patient transportation. Median delay of diagnosing SE was 2 h 10 min. EEG-based diagnosis was significantly delayed compared to clinical diagnosis. Median delay in recording EEG was 22 h 2 min. Median delay of the first medication was 35 min, and those of second- and third-stage medications were 3 h and 2 h 55 min, respectively. We applied stepwise definition for treatment response and counted delays accordingly: total convulsion period 5 h 52 min, Burst-suppression (BS) 17 h 30 min and return of consciousness 47 h 40 min. Median treatment period in intensive care unit was 2.7 days. Mortality over treatment period (median 7.7 days) was 8.5 %. No post-discharge follow-up was performed.

Conclusion

Our study reveals unexpectedly and unacceptably long delays in SE management, stressing the importance of commitment to acknowledged management protocol. Delays in the treatment can and need to be shortened markedly by several strategies discussed in this article.

Keywords

Convulsion Seizure Epilepsy Prehospital 

References

  1. 1.
    Aminoff MJ, Simon RP. Status epilepticus: causes, clinical features and consequences in 98 patients. Am J Med. 1980;69:657–66.PubMedCrossRefGoogle Scholar
  2. 2.
    Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia. 1994;35(1):27–34.PubMedCrossRefGoogle Scholar
  3. 3.
    DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46:1029–35.PubMedCrossRefGoogle Scholar
  4. 4.
    Claassen J, Lokin JK, Fitzsimmons B-FM, Mendelsohn FA, Mayer SA. Predictors of functional disability and mortality after status epilepticus. Neurology. 2002;58:139–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol. 2005;62:1698–702.PubMedCrossRefGoogle Scholar
  6. 6.
    Chin RFM, Neville BGR, Peckham C, Wade A, Bedford H, Scott RC. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol. 2008;7:696–703.PubMedCrossRefGoogle Scholar
  7. 7.
    Neligan A, Shorvon SD. Prognostic factors, morbidity and mortality in tonic-clonic status epilepticus: a review. Epilepsy Res. 2011;93:1–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Legriel S, Mourvillier B, Bele N, et al. Outcomes in 140 critically ill patients with status epilepticus. Intensive Care Med. 2008;34:476–80.PubMedCrossRefGoogle Scholar
  9. 9.
    Lotham E. The biochemical basis and pathophysiology of status epilepticus. Neurology. 1990;40(suppl):13–23.Google Scholar
  10. 10.
    DeGiorgio CM, Tomiyasu U, Gott PS, Treiman DM. Hippocampal pyramidal cell loss in human status epilepticus. Epilepsia. 1992;33:23–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Grabenstatter HL, Russek SJ, Brooks-Kayal AR. Molecular pathways controlling inhibitory receptor expression. Epilepsia. 2012;53(suppl 9):71–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci. 2005;25(34):7724–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Mayer SA, Claassen J, Lokin J, Mendelson F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors and impact on outcome. Arch Neurol. 2002;59:205–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Drislane FW, Blum AS, Lopez MR, Gautam S, Schomer DL. Duration on refractory status epilepticus and outcome: loss of prognostic utility after several hours. Epilepsia. 2009;50(6):1566–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Kalita J, Nair PP, Misra UK. A clinical, radiological and outcome study of status epilepticus from India. J Neurol. 2010;257:224–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Pellock JM, Marmarou A, DeLorenzo R. Time to treatment in prolonged seizure episodes. Epilepsy Behav. 2004;5:192–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Hesdorffer DC, Logroscino G, Cascino G, Annegers JF, Hauser WA. Insidence of status epilepticus in Rochester, Minnesota, 1965–1984. Neurology. 1998;50:735–41.PubMedCrossRefGoogle Scholar
  18. 18.
    Coeytaux A, Jallon P, Galobardes B, Morabia A. Incidence of status epilepticus in French-speaking Switzerland (EPISTAR). Neurology. 2000;55:693–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Parviainen I, Uusaro A, Kälviäinen R, Kaukanen E, Mervaala E, Ruokonen E. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology. 2002;59:1249–51.PubMedCrossRefGoogle Scholar
  20. 20.
    Parviainen I, Uusaro A, Kälviäinen R, Mervaala E, Ruokonen E. Propofol in the treatment of refractory status epilepticus. Intensive Care Med. 2006;32:1075–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology. 1993;43:483–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Aranda A, Fuocart G, Ducasse JL, Grolleau S, McGonical A, Valton L. Generalized convulsive status epilepticus management in adults: a cohort study with evaluation of professional practice. Epilepsia. 2010;51(10):2159–67.PubMedCrossRefGoogle Scholar
  23. 23.
    Trinka E. What is the evidence to use new intravenous AEDs in status epilepticus? Epilepsia. 2011;52(Suppl.8):35–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2011;259:645–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Navarro V, Dagron C, Demeret S, et al. A prehospital randomized trial in convulsive status epilepticus. Epilepsia. 2012;52(Suppl.8):48–9.Google Scholar
  26. 26.
    Liu X, Wu Y, Chen Z, Ma M, Su L. A systematic review of randomized controlled trials on the therapeutic effect of intravenous sodium valproate in status epilepticus. Int J Neurosci. 2012;122:277–83.PubMedCrossRefGoogle Scholar
  27. 27.
    Power KN, Flatten H, Gilhus NE, Engelsen BA. Propofol treatment in adult refractory status epilepticus. Mortality risk and outcome. Epilepsy Res. 2011;94:53–60.PubMedCrossRefGoogle Scholar
  28. 28.
    Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systemic review. Epilepsia. 2002;43(2):146–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Rossetti AO, Milligan TA, Vulliémoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2010;14:4–10.CrossRefGoogle Scholar
  30. 30.
    Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med. 2009;37(12):3024–30.PubMedCrossRefGoogle Scholar
  31. 31.
    DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia. 1998;39(8):833–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatr. 2005;76:534–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802–18.PubMedCrossRefGoogle Scholar
  34. 34.
    Krishnamurthy KB, Drislane FW. Depth of EEG suppression and outcome in barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia. 1999;40(6):759–62.PubMedCrossRefGoogle Scholar
  35. 35.
    Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17:348–55.PubMedCrossRefGoogle Scholar
  36. 36.
    Yaffe K, Lowenstein DH. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology. 1993;43(5):895–900.PubMedCrossRefGoogle Scholar
  37. 37.
    Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia. 1996;37(9):863–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Holtkamp M, Othman J, Buchheim K, Masuhr F, Schielke E, Meierkord H. A “Malignant” of status epilepticus. Arch Neurol. 2005;62:1428–31.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of HelsinkiHelsinkiFinland
  2. 2.Department of SurgeryHelsinki University Central HospitalHelsinkiFinland
  3. 3.Department of NeurologyUniversity of TurkuTurkuFinland
  4. 4.EspooFinland

Personalised recommendations